Holen Sie sich die Stockscreener-App
3.84
3.03%
-0.12
Handel nachbörslich:
3.82
-0.02
-0.52%
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Is Recursion (RXRX) Gaining Lasting Strategic Credibility From Its Expanded Russell Index Presence? - simplywall.st
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Form 144 RECURSION PHARMACEUTICALS For: 7 July By Investing.com - Investing.com UK
RXRX: Founder’s 40,000 Class A shares listed; insider sales reported (RXRX) - Stock Titan
Recursion Pharmaceuticals (NASDAQ:RXRX) stock gains as short interest and Russell flows hit AI-biotech rally - TechStock²
Form 144 RECURSION PHARMACEUTICALS For: 6 July By Investing.com - Investing.com Canada
Insider sells 340,440 RXRX shares (NASDAQ: RXRX) - Stock Titan
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed? - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus - TechStock²
Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation - Quiver Quantitative
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock - Investing.com
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock By Investing.com - Investing.com UK
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Globe and Mail
RXRX rallies past biotech ETFs as short interest, insider-sale filings shape coming week - TechStock²
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain - Moomoo
RXRXRecursion Pharmaceuticals Inc Volatility & Greeks - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) pops, short interest still much bigger than new founder-sale alert - TechStock²
Form 4 Recursion Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares - Stock Titan
Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant - Stock Titan
RXRX Stock Draws ARK Buying As AI Drug Story Builds - timothysykes.com
Christopher C. Gibson lists multiple Class A sales (RXRX) - Stock Titan
Form 144 RECURSION PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares - Stock Titan
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Anthropic Launches Claude Science to Enter Life Sciences, AI Drug Discovery Stocks Tumble in Response - NAI500
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Does Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value? - simplywall.st
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 2000 Value Benchmark - marketscreener.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on ARK Invest's Recent Share Purchase - Moomoo
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000E Value Benchmark - marketscreener.com
Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) ascends while market falls: Some facts to note - MSN
RXRX Stock Gains Attention As ARK Investment Steps In - timothysykes.com
Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX) - TradingView
Recursion Pharmaceuticals Stock Short Interest Rises to 36.75% - Quiver Quantitative
8RL Forecast — Price Target — Prediction for 2027 - TradingView
Cathie Wood's investment moves on June 25! Added over 890,000 shares of Recursion Pharmaceuticals in a major purchase, while selling more than 170,000 shares of Alibaba - Moomoo
Did Recursion Pharmaceuticals' Q4 Beat Signal a Turning Point - Kavout | AI
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying - The Globe and Mail
Enterprise value to EBIT forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) Short Interest & Short Float | Updated Jun 2026 $RXRX - MarketBeat
Why Could (NASDAQ:RXRX) Stay on Nasdaq Composite Radar? - Kalkine Media
Recursion Pharmaceuticals (RXRX) Sees Bulk Purchase from ARK Inv - GuruFocus
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Q4 2025 earnings summary - Quartr
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Institutional Confidence - TradingKey
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Sun Elaine D - Moomoo
Form 4 Recursion Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Australia
Recursion (RXRX) director receives 88,424 restricted stock units award - Stock Titan
Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grant - Stock Titan
Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units - Stock Titan
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):